{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:58:17Z","timestamp":1792897097025,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:00:00Z","timestamp":1734393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:00:00Z","timestamp":1734393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"This work was supported by Scientists in the Bureau of Science and Technology of ShaoGuan","award":["230329238033088"],"award-info":[{"award-number":["230329238033088"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s11060-024-04910-0","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T13:38:37Z","timestamp":1734442717000},"page":"239-247","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["MR perfusion characteristics of pseudoprogression in brain tumors treated with immunotherapy \u2013 a comparative study with chemo-radiation induced pseudoprogression and radiation necrosis"],"prefix":"10.1007","volume":"172","author":[{"given":"Hongyan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guirong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denes","family":"Szekeres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajnish","family":"Bharadwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry Z.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,17]]},"reference":[{"key":"4910_CR1","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1200\/JCO.23.01059","volume":"41","author":"PY Wen","year":"2023","unstructured":"Wen PY, van den Bent M, Youssef G et al (2023) RANO 2.0: update to the Response Assessment in Neuro-Oncology Criteria for High- and low-Grade gliomas in adults. J Clin Oncol 41:5187\u20135199","journal-title":"J Clin Oncol"},{"key":"4910_CR2","doi-asserted-by":"publisher","first-page":"e239003","DOI":"10.1148\/radiol.239003","volume":"306","author":"L Dercle","year":"2023","unstructured":"Dercle L, Sun S, Seban RD et al (2023) Emerging and evolving concepts in Cancer Immunotherapy Imaging. Radiology 306:e239003","journal-title":"Radiology"},{"key":"4910_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1148\/radiol.2018181349","volume":"290","author":"M Nishino","year":"2019","unstructured":"Nishino M, Hatabu H, Hodi FS (2019) Imaging of Cancer Immunotherapy: current approaches and future directions. Radiology 290:9\u201322","journal-title":"Radiology"},{"key":"4910_CR4","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s13311-016-0507-6","volume":"14","author":"BM Ellingson","year":"2017","unstructured":"Ellingson BM, Wen PY, Cloughesy TF (2017) Modified Criteria for Radiographic Response Assessment in Glioblastoma clinical trials. Neurotherapeutics 14:307\u2013320","journal-title":"Neurotherapeutics"},{"key":"4910_CR5","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","volume":"16","author":"NU Lin","year":"2015","unstructured":"Lin NU, Lee EQ, Aoyama H et al (2015) Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol 16:e270\u2013278","journal-title":"Lancet Oncol"},{"key":"4910_CR6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3174\/ajnr.A4474","volume":"37","author":"S Wang","year":"2016","unstructured":"Wang S, Martinez-Lage M, Sakai Y et al (2016) Differentiating Tumor Progression from Pseudoprogression in patients with Glioblastomas using Diffusion Tensor Imaging and Dynamic susceptibility contrast MRI. AJNR Am J Neuroradiol 37:28\u201336","journal-title":"AJNR Am J Neuroradiol"},{"key":"4910_CR7","doi-asserted-by":"publisher","first-page":"e0270216","DOI":"10.1371\/journal.pone.0270216","volume":"17","author":"M Roques","year":"2022","unstructured":"Roques M, Catalaa I, Raveneau M et al (2022) Assessment of the hypervascularized fraction of glioblastomas using a volume analysis of dynamic susceptibility contrast-enhanced MRI may help to identify pseudoprogression. PLoS ONE 17:e0270216","journal-title":"PLoS ONE"},{"key":"4910_CR8","doi-asserted-by":"publisher","first-page":"1046629","DOI":"10.3389\/fonc.2023.1046629","volume":"13","author":"A Anil","year":"2023","unstructured":"Anil A, Stokes AM, Chao R et al (2023) Identification of single-dose, dual-echo based CBV threshold for fractional tumor burden mapping in recurrent glioblastoma. Front Oncol 13:1046629","journal-title":"Front Oncol"},{"key":"4910_CR9","doi-asserted-by":"publisher","first-page":"111076","DOI":"10.1016\/j.ejrad.2023.111076","volume":"167","author":"N Nierobisch","year":"2023","unstructured":"Nierobisch N, Ludovichetti R, Kadali K et al (2023) Comparison of clinically available dynamic susceptibility contrast post processing software to differentiate progression from pseudoprogression in post-treatment high grade glioma. Eur J Radiol 167:111076","journal-title":"Eur J Radiol"},{"key":"4910_CR10","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3174\/ajnr.A1362","volume":"30","author":"RF Barajas","year":"2009","unstructured":"Barajas RF, Chang JS, Sneed PK, Segal MR, McDermott MW, Cha S (2009) Distinguishing recurrent intra-axial metastatic tumor from radiation necrosis following gamma knife radiosurgery using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. AJNR Am J Neuroradiol 30:367\u2013372","journal-title":"AJNR Am J Neuroradiol"},{"key":"4910_CR11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11060-009-0106-z","volume":"99","author":"K Mitsuya","year":"2010","unstructured":"Mitsuya K, Nakasu Y, Horiguchi S et al (2010) Perfusion weighted magnetic resonance imaging to distinguish the recurrence of metastatic brain tumors from radiation necrosis after stereotactic radiosurgery. J Neurooncol 99:81\u201388","journal-title":"J Neurooncol"},{"key":"4910_CR12","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.mri.2011.04.004","volume":"29","author":"J Huang","year":"2011","unstructured":"Huang J, Wang AM, Shetty A et al (2011) Differentiation between intra-axial metastatic tumor progression and radiation injury following fractionated radiation therapy or stereotactic radiosurgery using MR spectroscopy, perfusion MR imaging or volume progression modeling. Magn Reson Imaging 29:993\u20131001","journal-title":"Magn Reson Imaging"},{"key":"4910_CR13","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.crad.2018.04.006","volume":"73","author":"B Wang","year":"2018","unstructured":"Wang B, Zhao B, Zhang Y et al (2018) Absolute CBV for the differentiation of recurrence and radionecrosis of brain metastases after gamma knife radiotherapy: a comparison with relative CBV. Clin Radiol 73:758 e751-758 e757","journal-title":"Clin Radiol"},{"key":"4910_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13014-019-1271-7","volume":"14","author":"R Morabito","year":"2019","unstructured":"Morabito R, Alafaci C, Pergolizzi S et al (2019) DCE and DSC perfusion MRI diagnostic accuracy in the follow-up of primary and metastatic intra-axial brain tumors treated by radiosurgery with cyberknife. Radiat Oncol 14:65","journal-title":"Radiat Oncol"},{"key":"4910_CR15","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41573-021-00345-8","volume":"21","author":"AJ Korman","year":"2022","unstructured":"Korman AJ, Garrett-Thomson SC, Lonberg N (2022) The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nat Rev Drug Discov 21:509\u2013528","journal-title":"Nat Rev Drug Discov"},{"key":"4910_CR16","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1148\/radiol.2021210760","volume":"302","author":"DA Smith","year":"2022","unstructured":"Smith DA, Kikano E, Tirumani SH, de Lima M, Caimi P, Ramaiya NH (2022) Imaging-based Toxicity and Response Pattern Assessment following CAR T-Cell therapy. Radiology 302:438\u2013445","journal-title":"Radiology"},{"key":"4910_CR17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12935-023-02902-0","volume":"23","author":"HE Marei","year":"2023","unstructured":"Marei HE, Hasan A, Pozzoli G, Cenciarelli C (2023) Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired. Cancer Cell Int 23:64","journal-title":"Cancer Cell Int"},{"key":"4910_CR18","doi-asserted-by":"publisher","unstructured":"Alimonti P, Gonzalez Castro LN (2023) The current Landscape of Immune checkpoint inhibitor immunotherapy for primary and metastatic brain tumors. Antibodies (Basel) 12(2):27. https:\/\/doi.org\/10.3390\/antib12020027","DOI":"10.3390\/antib12020027"},{"key":"4910_CR19","doi-asserted-by":"publisher","first-page":"e534","DOI":"10.1016\/S1470-2045(15)00088-1","volume":"16","author":"H Okada","year":"2015","unstructured":"Okada H, Weller M, Huang R et al (2015) Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol 16:e534\u2013e542","journal-title":"Lancet Oncol"},{"key":"4910_CR20","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40259-020-00425-y","volume":"34","author":"M Frelaut","year":"2020","unstructured":"Frelaut M, du Rusquec P, de Moura A, Le Tourneau C, Borcoman E (2020) Pseudoprogression and Hyperprogression as New forms of response to Immunotherapy. BioDrugs 34:463\u2013476","journal-title":"BioDrugs"},{"key":"4910_CR21","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.3348\/kjr.2022.0225","volume":"23","author":"N Kim","year":"2022","unstructured":"Kim N, Lee ES, Won SE et al (2022) Evolution of Radiological Treatment Response assessments for Cancer Immunotherapy: from iRECIST to Radiomics and Artificial Intelligence. Korean J Radiol 23:1089\u20131101","journal-title":"Korean J Radiol"},{"key":"4910_CR22","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s00330-020-07249-y","volume":"31","author":"FS Ahmed","year":"2021","unstructured":"Ahmed FS, Dercle L, Goldmacher GV et al (2021) Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial. Eur Radiol 31:1853\u20131862","journal-title":"Eur Radiol"},{"key":"4910_CR23","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1080\/02841850600815341","volume":"47","author":"L Stenberg","year":"2006","unstructured":"Stenberg L, Englund E, Wirestam R, Siesj\u00f6 P, Salford LG, Larsson EM (2006) Dynamic susceptibility contrast-enhanced perfusion magnetic resonance (MR) imaging combined with contrast-enhanced MR imaging in the follow-up of immunogene-treated glioblastoma multiforme. Acta Radiol 47:852\u2013861","journal-title":"Acta Radiol"},{"key":"4910_CR24","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00234-010-0802-6","volume":"53","author":"M Vrabec","year":"2011","unstructured":"Vrabec M, Van Cauter S, Himmelreich U et al (2011) MR perfusion and diffusion imaging in the follow-up of recurrent glioblastoma treated with dendritic cell immunotherapy: a pilot study. Neuroradiology 53:721\u2013731","journal-title":"Neuroradiology"},{"key":"4910_CR25","doi-asserted-by":"crossref","unstructured":"Cuccarini V, Aquino D, Gioppo A et al (2019) Advanced MRI Assessment during dendritic cell Immunotherapy added to Standard Treatment against Glioblastoma. J Clin Med 8","DOI":"10.3390\/jcm8112007"},{"key":"4910_CR26","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1093\/neuonc\/noaa066","volume":"22","author":"J Song","year":"2020","unstructured":"Song J, Kadaba P, Kravitz A et al (2020) Multiparametric MRI for early identification of therapeutic response in recurrent glioblastoma treated with immune checkpoint inhibitors. Neuro Oncol 22:1658\u20131666","journal-title":"Neuro Oncol"},{"key":"4910_CR27","doi-asserted-by":"crossref","unstructured":"Chawla S, Shehu V, Gupta PK, Nath K, Poptani H (2021) Physiological imaging methods for evaluating response to immunotherapies in Glioblastomas. Int J Mol Sci 22","DOI":"10.3390\/ijms22083867"},{"key":"4910_CR28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.mric.2023.07.003","volume":"32","author":"J Lee","year":"2024","unstructured":"Lee J, Chen MM, Liu HL, Ucisik FE, Wintermark M, Kumar VA (2024) MR Perfusion Imaging for Gliomas. Magn Reson Imaging Clin N Am 32:73\u201383","journal-title":"Magn Reson Imaging Clin N Am"},{"key":"4910_CR29","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S1470-2045(08)70125-6","volume":"9","author":"D Brandsma","year":"2008","unstructured":"Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9:453\u2013461","journal-title":"Lancet Oncol"},{"key":"4910_CR30","doi-asserted-by":"publisher","unstructured":"Liu X, Chen H, Tan G et al (2024) A comprehensive neuroimaging review of the primary and metastatic brain tumors treated with immunotherapy: current status, and the application of advanced imaging approaches and artificial intelligence. Frontiers in Immunology. https:\/\/doi.org\/10.3389\/fimmu.2024.1496627","DOI":"10.3389\/fimmu.2024.1496627"},{"key":"4910_CR31","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2463\/mrms.mp.2016-0036","volume":"16","author":"K Kudo","year":"2017","unstructured":"Kudo K, Uwano I, Hirai T et al (2017) Comparison of different post-processing algorithms for dynamic susceptibility contrast Perfusion Imaging of cerebral gliomas. Magn Reson Med Sci 16:129\u2013136","journal-title":"Magn Reson Med Sci"},{"key":"4910_CR32","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.neurad.2011.12.004","volume":"39","author":"N Mauz","year":"2012","unstructured":"Mauz N, Krainik A, Tropres I et al (2012) Perfusion magnetic resonance imaging: comparison of semiologic characteristics in first-pass perfusion of brain tumors at 1.5 and 3 Tesla. J Neuroradiol 39:308\u2013316","journal-title":"J Neuroradiol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04910-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-024-04910-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04910-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T22:13:09Z","timestamp":1739830389000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-024-04910-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,17]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["4910"],"URL":"https:\/\/doi.org\/10.1007\/s11060-024-04910-0","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,17]]},"assertion":[{"value":"21 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the ethics committees of the Yuebei People\u2019s Hospital, and the requirement for informed consent was waived (Date August 1, 2022 \/No. KY-2022-042).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The requirement for informed consent was waived.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}